ABOUT US
ATLyphe is a preclinical biotechnology spin-off from the ETH Zurich and University of Zurich.
Co-Founder, CSO
Renier Myburgh, PhD
Renier joined ATLyphe in July 2022 as co-Project Lead and Scientific Lead. In his role, he is responsible for pharmacological and toxicological studies as well as other research and development activities...
Co-Founder, CMO
Maddalena Marconato, MD
Maddalena joined ATLyphe in January 2023 as Medical Lead. In her role, she is responsible for developing our First-In-Human (FIH) clinical trial and supervising the conduct of the study...
Co-Founder, CEO
Danielle Villars, PhD
Danielle joined ATLyphe in November 2022 and took over the role as business lead and co-project lead in April 2023. In her role, she is responsible for all business affairs...
ADVISORS
Clinical and Scientific Advisor
Prof. Dr. Markus G. Manz
Prof. Markus G. Manz is department chair for medical oncology & hematology at USZ, chair of the Comprehensive Cancer Center Zürich and full Professor of Hematology at the University of Zurich...
Scientific and Business Advisor
Prof. Dario Neri
Prof. Dario Neri was a full Professor of Biomacromolecules at ETH Zürich. He was trained as a chemist under Nobel laureate Kurt Wüthrich at ETH and performed a postdoc under Nobel laureate...
Business Advisor
Dr. Claudine Blaser
Dr. Claudine Blaser is Managing Director of Medgate Switzerland. She studied natural sciences at the ETH Zurich, obtained her doctorate in immunology and completed an ETH master's degree...